These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36660669)

  • 1. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients.
    Zheng X; Zhang Y; Wang Y; He Z; Zhang Q; Ren D; Yan X; Yuan X
    Front Surg; 2023; 10():1052100. PubMed ID: 36936652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
    Liu GM; Zeng HD; Zhang CY; Xu JW
    Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
    Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
    Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
    [No Abstract]   [Full Text] [Related]  

  • 5. N6-methyladenosine associated prognostic model in hepatocellular carcinoma.
    Huang H; Bai Y; Lu X; Xu Y; Zhao H; Sang X
    Ann Transl Med; 2020 May; 8(10):633. PubMed ID: 32566570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma.
    Kong F; Wang K; Wang L
    Discov Oncol; 2022 Nov; 13(1):131. PubMed ID: 36434140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
    Wu X; Zhang X; Tao L; Dai X; Chen P
    Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cancer Genome Atlas (TCGA) based m
    Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
    Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma.
    Bian S; Ni W; Zhu M; Song Q; Zhang J; Ni R; Zheng W
    Front Mol Biosci; 2020; 7():604766. PubMed ID: 33363211
    [No Abstract]   [Full Text] [Related]  

  • 10. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
    Qi LW; Jia JH; Jiang CH; Hu JM
    Front Genet; 2020; 11():614566. PubMed ID: 33519919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
    Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma.
    Wu S; He G; Liu S; Cao Y; Geng C; Pan H
    Int J Med Sci; 2022; 19(4):618-630. PubMed ID: 35582419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
    Wang H; Cai H; Li L
    Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple m
    Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
    BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N
    Li G; Zhang Y; Du X; Li W; Zhang Y; Han T; Zheng Z
    Transl Cancer Res; 2020 Jan; 9(1):323-334. PubMed ID: 35117186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
    Zou Y; Jiang G; Xie Y; Li H
    Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
    Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
    Front Immunol; 2022; 13():918140. PubMed ID: 35833147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.